Bray F. Ferlay J. Soerjomataram I. Siegel R.L. Torre L.A. Jemal A.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 68: 394-424https://doi.org/10.3322/caac.21492

Hortobagyi, G.N., Connolly, J.L., D'Orsi, C.J., Edge, S.B., Mittendorf, E.A., Rugo, H.S., Solin, L.J., Weaver, D.L., Winchester, D.J., Giuliano, A., 2017. Breast, in: Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., Sullivan, D.C., Jessup, J.M., Brierley, J.D., Gaspar, L.E., Schilsky, R.L., Balch, C.M., Winchester, D.P., Asare, E.A., Madera, M., Gress, D.M., Meyer, L.R. (Eds.), AJCC Cancer Staging Manual. Springer International Publishing, Cham, pp. 589–636. https://doi.org/10.1007/978-3-319-40618-3_48.

Hortobagyi G.N. Edge S.B. Giuliano A.

New and important changes in the TNM staging system for breast cancer.

Am Soc Clin Oncol Educ Book. 38: 457-467https://doi.org/10.1200/EDBK_201313Auguste A. Cortet M. Dabakuyo-Yonli T.S. Launay L. Arnould L. Desmoulins I. Roignot P. Darut-Jouve A. Poillot M.-L. Bertaut A. Arveux P.

Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study.

PLoS One. 12https://doi.org/10.1371/journal.pone.0170069Awadelkarim K.D. Arizzi C. Elamin E.O.M. Hamad H.M.A. De Blasio P. Mekki S.O. Osman I. Biunno I. Elwali N.E. Mariani-Costantini R. Barberis M.C.

Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa.

Histopathology. 52: 445-456https://doi.org/10.1111/j.1365-2559.2008.02966.xDeSantis C.E. Ma J. Gaudet M.M. Newman L.A. Miller K.D. Goding Sauer A. Jemal A. Siegel R.L.

Breast cancer statistics, 2019.

CA Cancer J Clin. 69: 438-451https://doi.org/10.3322/caac.21583Howlader N. Altekruse S.F. Li C.I. Chen V.W. Clarke C.A. Ries L.A.G. Cronin K.A.

US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.

J Natl. Cancer Inst. 106https://doi.org/10.1093/jnci/dju055Puig-Vives M. Sánchez M.J. Sánchez-Cantalejo J. Torrella-Ramos A. Martos C. Ardanaz E. Chirlaque M.D. Perucha J. Díaz J.M. Mateos A. Machón M. Marcos-Gragera R.

Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.

Gynecologic Oncology. 130: 609-614https://doi.org/10.1016/j.ygyno.2013.05.039Hamer J. McDonald R. Zhang L. Verma S. Leahey A. Ecclestone C. Bedard G. Pulenzas N. Bhatia A. Chow R. DeAngelis C. Ellis J. Rakovitch E. Lee J. Chow E.

Quality of life (QOL) and symptom burden (SB) in patients with breast cancer.

Support Care Cancer. 25: 409-419https://doi.org/10.1007/s00520-016-3417-6

Breast cancer treatment: a review.

JAMA. 321: 288-300https://doi.org/10.1001/jama.2018.19323Cardoso F. Kyriakides S. Ohno S. Penault-Llorca F. Poortmans P. Rubio I.T. Zackrisson S. Senkus E.

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Ann. Oncol. 30: 1194-1220https://doi.org/10.1093/annonc/mdz173Denduluri N. Chavez-MacGregor M. Telli M.L. Eisen A. Graff S.L. Hassett M.J. Holloway J.N. Hurria A. King T.A. Lyman G.H. Partridge A.H. Somerfield M.R. Trudeau M.E. Wolff A.C. Giordano S.H.

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

J Clin Oncol. https://doi.org/10.1200/JCO.2018.78.8604Denduluri N. Somerfield M.R. Eisen A. Holloway J.N. Hurria A. King T.A. Lyman G.H. Partridge A.H. Telli M.L. Trudeau M.E. Wolff A.C.

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: an American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

J Clin Oncol. 34: 2416-2427https://doi.org/10.1200/JCO.2016.67.0182Center for Drug Evaluation and Research

Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims [WWW Document].

U.S. Food and Drug Administration, ()Frank L. Basch E. Selby J.V.

The PCORI perspective on patient-centered outcomes research.

JAMA. 312: 1513-1514https://doi.org/10.1001/jama.2014.11100

New European guidance on patient-reported outcomes.

The Lancet Oncology. 17: e226https://doi.org/10.1016/S1470-2045(16)30113-9Riis C.L. Bechmann T. Jensen P.T. Coulter A. Steffensen K.D.

Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review.

Patient Relat Outcome Meas. 10: 117-127https://doi.org/10.2147/PROM.S195296Stefanovic S. Wallwiener M. Karic U. Domschke C. Katic L. Taran F.-A. Pesic A. Hartkopf A. Hadji P. Teufel M. Schuetz F. Sohn C. Fasching P. Schneeweiss A. Brucker S.

Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications.

Support Care Cancer. 25: 549-558https://doi.org/10.1007/s00520-016-3437-2Reed E. Simmonds P. Haviland J. Corner J.

Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey.

J Pain Symptom Manage. 43: 747-758https://doi.org/10.1016/j.jpainsymman.2011.05.005Shin J.A. El-Jawahri A. Parkes A. Schleicher S.M. Knight H.P. Temel J.S.

Quality of life, mood, and prognostic understanding in patients with metastatic breast cancer.

J Palliat Med. 19: 863-869https://doi.org/10.1089/jpm.2016.0027Wood R. Mitra D. de Courcy J. Iyer S.

Patient-reported quality of life and treatment satisfaction in patients with HR+/HER2- advanced/metastatic breast cancer.

Clin Ther. 39: 1719-1728https://doi.org/10.1016/j.clinthera.2017.07.009Wood R. Mitra D. de Courcy J. Iyer S.

Patient-reported pain severity, pain interference and health status in HR+/HER2- advanced/metastatic breast cancer.

ESMO Open. 2e000227https://doi.org/10.1136/esmoopen-2017-000227Avis N.E. Levine B. Goyal N. Crawford S.L. Hess R. Colvin A. Bromberger J.T. Greendale G.A.

Health-related quality of life among breast cancer survivors and noncancer controls over 10 years: Pink SWAN.

Cancer. 126: 2296-2304https://doi.org/10.1002/cncr.32757Lazarewicz M.A. Wlodarczyk D. Lundgren S. Reidunsdatter R.J.

Diversity in changes of HRQoL over a 1-year period after radiotherapy in Norwegian breast cancer patients: results of cluster analyses.

Qual Life Res. 28: 1521-1530https://doi.org/10.1007/s11136-019-02127-7Di Maio M. Perrone F. Conte P.

Real-world evidence in oncology: opportunities and limitations.

Oncologist. 25: e746-e752https://doi.org/10.1634/theoncologist.2019-0647Anderson P. Benford M. Harris N. Karavali M. Piercy J.

Real-world physician and patient behaviour across countries: Disease-Specific Programmes—a means to understand.

Curr Med Res Opin. 24: 3063-3072https://doi.org/10.1185/03007990802457040Brady M.J. Cella D.F. Mo F. Bonomi A.E. Tulsky D.S. Lloyd S.R. Deasy S. Cobleigh M. Shiomoto G.

Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

J Clin Oncol. 15: 974-986https://doi.org/10.1200/JCO.1997.15.3.974Brucker P.S. Yost K. Cashy J. Webster K. Cella D.

General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G).

Eval Health Prof. 28: 192-211https://doi.org/10.1177/0163278705275341Herdman M. Gudex C. Lloyd A. Janssen M. Kind P. Parkin D. Bonsel G. Badia X.

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Qual Life Res. 20: 1727-1736https://doi.org/10.1007/s11136-011-9903-xPickard A.S. Law E.H. Jiang R. Pullenayegum E. Shaw J.W. Xie F. Oppe M. Boye K.S. Chapman R.H. Gong C.L. Balch A. Busschbach J.J.V.

United States valuation of EQ-5D-5L health states using an international protocol.

Value Health. 22: 931-941https://doi.org/10.1016/j.jval.2019.02.009Shiroiwa T. Fukuda T. Ikeda S. Igarashi A. Noto S. Saito S. Shimozuma K.

Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D.

Qual Life Res. 25: 707-719https://doi.org/10.1007/s11136-015-1108-2Andrade L.F. Ludwig K. Goni J.M.R. Oppe M. de Pouvourville G.

A French value set for the EQ-5D-5L.

Pharmacoeconomics. 38: 413-425https://doi.org/10.1007/s40273-019-00876-4Ludwig K. Graf von der Schulenburg J.-M. Greiner W.

German value set for the EQ-5D-5L.

Pharmacoeconomics. 36: 663-674https://doi.org/10.1007/s40273-018-0615-8Ramos-Goñi J.M. Craig B.M. Oppe M. Ramallo-Fariña Y. Pinto-Prades J.L. Luo N. Rivero-Arias O.

Handling data quality issues to estimate the Spanish EQ-5D-5L value set using a hybrid interval regression approach.

Value Health. 21: 596-604https://doi.org/10.1016/j.jval.2017.10.023van Hout B. Janssen M.F. Feng Y.-S. Kohlmann T. Busschbach J. Golicki D. Lloyd A. Scalone L. Kind P. Pickard A.S.

Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.

Value Health. 15: 708-715https://doi.org/10.1016/j.jval.2012.02.008

Modeling valuations for EuroQol health states.

Medical Care. 35: 1095-1108

Position statement on use of the EQ-5D-5L value set for England [WWW Document].

NICE, () Jiang R. Janssen B. Pickard A.S.

US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples.

Qual Life Res. 29https://doi.org/10.1007/s11136-020-02650-ySzende A. Janssen B. Cabases J.

Self-Reported Population Health: An International Perspective based on EQ-5D.

Springer, Janssen M.F. Szende A. Cabases J. Ramos-Goñi J.M. Vilagut G. König H.H.

Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries.

Eur J Health Econ. 20: 205-216https://doi.org/10.1007/s10198-018-0955-5Hinz A. Kohlmann T. Stöbel-Richter Y. Zenger M. Brähler E.

The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population.

Qual Life Res. 23: 443-447https://doi.org/10.1007/s11136-013-0498-2Huber M.B. Felix J. Vogelmann M. Leidl R.

Health-Related quality of life of the general German population in 2015: results from the EQ-5D-5L.

Int J Environ Res Public Health. 14https://doi.org/10.3390/ijerph14040426Hernandez G. Garin O. Pardo Y. Vilagut G. Pont À. Suárez M. Neira M. Rajmil L. Gorostiza I. Ramallo-Fariña Y. Cabases J. Alonso J. Ferrer M.

Validity of the EQ-5D-5L and reference norms for the Spanish population.

Qual Life Res. 27: 2337-2348https://doi.org/10.1007/s11136-018-1877-5Charlson M.E. Charlson R.E. Peterson J.C. Marinopoulos S.S. Briggs W.M. Hollenberg J.P.

The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients.

J Clin Epidemiol. 61: 1234-1240https://doi.org/10.1016/j.jclinepi.2008.01.006Eton D.T. Cella D. Yost K.J. Yount S.E. Peterman A.H. Neuberg D.S. Sledge G.W. Wood W.C.

A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale.

J Clin Epidemiol. 57: 898-910https://doi.org/10.1016/j.jclinepi.2004.01.012Nemeth B.T. Varga Z.V. Wu W.J. Pacher P.

Trastuzumab cardiotoxicity: from clinical trials to experimental studies.

Br J Pharmacol. 174: 3727-3748https://doi.org/10.1111/bph.13643Vadaparampil S.T. Christie J. Donovan K.A. Kim J. Augusto B. Kasting M.L. Holt C.L. Ashing K. Halbert C.H. Pal T.

Health-related quality of life in Black breast cancer survivors with and without triple-negative breast cancer (TNBC).

Breast Cancer Res Treat. 163: 331-342https://doi.org/10.1007/s10549-017-4173-0Runowicz C.D. Leach C.R. Henry N.L. Henry K.S. Mackey H.T. Cowens-Alvarado R.L. Cannady R.S. Pratt-Chapman M.L. Edge S.B. Jacobs L.A. Hurria A. Marks L.B. LaMonte S.J. Warner E. Lyman G.H. Ganz P.A.

American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

J Clin Oncol. https://doi.org/10.1200/JCO.2015.64.3809Pan H. Gray R. Braybrooke J. Davies C. Taylor C. McGale P. Peto R. Pritchard K.I. Bergh J. Dowsett M. Hayes D.F. EBCTCG

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

N Engl J Med. 377: 1836-1846https://doi.org/10.1056/NEJMoa1701830de Ligt K.M. Heins M. Verloop J. Ezendam N.P.M. Smorenburg C.H. Korevaar J.C. Siesling S.

The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors.

Breast Cancer Res Treat. 178: 703-711https://doi.org/10.1007/s10549-019-05433-3Enien M.A. Ibrahim N. Makar W. Darwish D. Gaber M.

Health-related quality of life: Impact of surgery and treatment modality in breast cancer.

J Cancer Res Ther. 14: 957-963https://doi.org/10.4103/0973-1482.183214Ecclestone C. Chow R. Pulenzas N. Zhang L. Leahey A. Hamer J. DeAngelis C. Bedard G. McDonald R. Bhatia A. Ellis J. Rakovitch E. Vuong S. Chow E. Verma S.

Quality of life and symptom burden in patients with metastatic breast cancer.

Support Care Cancer. 24: 4035-4043https://doi.org/10.1007/s00520-016-3217-zHuang H.-Y. Tsai W.-C. Chou W.-Y. Hung Y.-C. Liu L.-C. Huang K.-F. Wang W.-C. Leung K.-W. Hsieh R.-K. Kung P.-T.

Quality of life of breast and cervical cancer survivors.

BMC Womens Health. 17https://doi.org/10.1186/s12905-017-0387-xMarschner N. Trarbach T. Rauh J. Meyer D. Müller-Hagen S. Harde J. Dille S. Kruggel L. Jänicke M. TMK-Group (Tumour Registry Breast Cancer)

Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project.

Breast Cancer Res Treat. 175: 701-712https://doi.org/10.1007/s10549-019-05197-wMüller V. Nabieva N. Häberle L. Taran F.-A. Hartkopf A.D. Volz B. Overkamp F. Brandl A.L. Kolberg H.-C. Hadji P. Tesch H. Ettl J. Lux M.P. Lüftner D. Belleville E. Fasching P.A. Janni W. Beckmann M.W. Wimberger P. Hielscher C. Fehm T.N. Brucker S.Y. Wallwiener D. Schneeweiss A. Wallwiener M.

Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry.

The Breast. 37: 154-160https://doi.org/10.1016/j.breast.2017.08.008Francis P.A. Regan M.M. Fleming G.F. Láng I. Ciruelos E. Bellet M. Bonnefoi H.R. Climent M.A. Da Prada G.A. Burstein H.J. Martino S. Davidson N.E. Geyer C.E. Walley B.A. Coleman R. Kerbrat P. Buchholz S. Ingle J.N. Winer E.P. Rabaglio-Poretti M. Maibach R. Ruepp B. Giobbie-Hurder A. Price K.N. Colleoni M. Viale G. Coates A.S. Goldhirsch A. Gelber R.D. SOFT Investigators, International Breast Cancer Study Group

Adjuvant ovarian suppression in premenopausal breast cancer.

N Engl J Med. 372: 436-446https://doi.org/10.1056/NEJMoa1412379Ribi K. Luo W. Bernhard J. Francis P.A. Burstein H.J. Ciruelos E. Bellet M. Pavesi L. Lluch A. Visini M. Parmar V. Tondini C. Kerbrat P. Perelló A. Neven P. Torres R. Lombardi D. Puglisi F. Karlsson P. Ruhstaller T. Colleoni M. Coates A.S. Goldhirsch A. Price K.N. Gelber R.D. Regan M.M. Fleming G.F.

Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial.

J Clin Oncol. https://doi.org/10.1200/JCO.2015.64.8675Baum M. Buzdar A. Cuzick J. Forbes J. Houghton J. Howell A. Sahmoud T. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.

Cancer. 98: 1802-1810https://doi.org/10.1002/cncr.11745Cella D. Fallowfield L. Barker P. Cuzick J. Locker G. Howell A. ATAC Trialistsa9 Group

Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer.

Breast Cancer Res Treat. 100: 273-284https://doi.org/10.1007/s10549-006-9260-6ATAC Trialists’ Group, The

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

The Lancet. 359: 2131-2139https://doi.org/10.1016/S0140-6736(02)09088-8